We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BioVendor Group

BioVendor Group is an international group of biotechnology companies (BioVendor LM, BioVendor R&D, TestLine, ViennaLa... read more Featured Products: More products

Download Mobile App





BioVendor Presents Latest Innovations in Immunodiagnostics and Molecular Diagnostics at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 06 Feb 2023

BioVendor Group (Brno, Czech Republic) is demonstrating its latest innovations in immunodiagnostics and molecular diagnostics at Medlab Middle East 2023. More...

At this year’s Medlab Middle East, BioVendor is presenting its growing CLIA portfolio of parameters, Microblot-Array multiplex diagnostics in microtiter plate format, other technologies, such as the revolutionary NGS technology fastGEN, and its unique methods using microRNAs. BioVendor is highlighting its CLIA portfolio of assays with a constantly growing number of parameters developed for the cutting-edge analyzer KleeYa. BioVendor Group’s CLIA portfolio currently includes 41 unique parameters. Its MxA Human Protein is the flagship of a total of 41 unique CLIA parameters that expand the possibilities of laboratories.

BioVendor is also highlighting Microblot-Array (MBA), a new generation of unique, immunoblot array in a microtiter plate format. It is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which can save time and lower costs. The Microblot-Array is a comprehensive solution for fast and accurate multiplex diagnostics. A combination of BLOT principle and ELISA workflow allows the use of existing laboratory equipment and keeps the setup costs down.

At Medlab Middle East 2023, BioVendor is showcasing its new technology fastGEN for examination of the mutation status of oncomarkers in samples. The technology is base on ultra-deep sequencing of short amplicons obtained by a single polymerase chain reaction with special tagged hybrid primers. The fastGEN technology is simple, ultra-sensitive, specific and effective - it is perfectly adapted to diagnostics and offers new advantages for clinical material. BioVendor highlighted its user-friendly diagnostic kits with software solution for KRAS, NRAS, BRAF, EGFR, IDH 1/2, POLE and CFTR genes with excellent analytical parameters and extremely fast processing.

Additionally, BioVendor is demonstrating its complete solution for miRNA/sncRNA projects starting with isolation, followed by screening for proper targets and final quantification of them. The small regulatory molecules, called microRNA or miRNA, have become emerging biomarkers for research in all fields of medical and biological sciences. This new miRNA regulatory domain empowers R&D, identifies novel disease biomarkers in biofluids and tissues and develops non-invasive screening and diagnostic tests. Using miRNA as pathological biomarkers is technically feasible, highly specific and sensitive from the earliest stages of the disease. BioVendor offers specific technologies based on patented RT-qPCR for sensitive detection and quantification of miRNA molecules. The technologies use multiplex detection format already used in life sciences research and clinical diagnostic applications.

Related Links:
BioVendor Group 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.